Page 129 - Tcs News Today

New TCS rule on foreign remittance will come into effect from October 1 | Latest News India

Experts said the governments statement is still ambiguous in intent and it appears that it is merely postponing a problem instead of resolving it conclusively

​Aggressive New Short means the average traded quantity of a stock for 5 days along with its cumulative open interest have increased whereas the price has decreased.

When Indias Information Technology Act came into being in October 2000, Facebook was four years away from its inception, the first iPhone wouldnt be launched for the next seven years, and the Nasdaq was experiencing an unprecedented implosion of the dotcom bubble. The internet has changed a lot since. Now, to replace the IT Act of 2000, the government is bringing the Digital India Act, the draft of which will be open for public consultation in the next two weeks. This and more in todays ETtech M...

The government will soon issue some clarifications on charging different TCS rates varying between 0.5% and 20%.

Also in the news. Tata Consultancy Services (TCS), one of the biggest IT firms in India, has been rocked by a bribes-for-jobs scandal. According to a report by Mint, a few senior personnel at the

​​Tata Tech had filed IPO papers with Sebi in March. The issue is completely an offer for sale (OFS), under which the selling shareholders will offload up to 9.57 crore units representing 23.60% of its paid-up share capital.

At an event, Goyal also expressed hope that procurement of goods and services from Government eMarketplace (GeM) would cross Rs 3 lakh crore this fiscal from above Rs 2 lakh crore in 2022-23.

Its bribes-for-jobs scandal should push all recruiters to place clean-ups over cover-ups, as the company has done, even for contractual hires. Market discipline would demand no less

The European Medicines Agencys (EMA) Committee has accepted Aurobindo Pharma subsidiary CuraTeQ Biologics request to withdraw the applications for marketing authorization of ZEFYLTI (a filgrastim biosimilar) and DYRUPEG (a pegfilgrastim biosimilar).